Zhou Jin-Yu, Wang Yu-Ming, Peng Qian-Ya, Hui Hong-Lei, Yin Ye
Department of Clinical Laboratory Examination, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, Yunnan Province, China.
Department of Clinical Laboratory Examination, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, Yunnan Province, China,E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Oct;28(5):1539-1544. doi: 10.19746/j.cnki.issn.1009-2137.2020.05.019.
To detect the expression level of LncRNA XLOC_109948 in bone marrow and serum of patients with acute myeloid Leukemia (AML), to verify the consistency between the expression in bone marrow and serum and to explore the role of LncRNA XLOC_109948 expression in the occurrence a development of AML.
Bone marrow and peripheral blood samples were collected from 62 patients with AML, including 36 patients with AML (AML group), 26 AML patients with complete remission (AML-CR group), and peripheral blood from 20 healthy persons (control group) were also collected. The expression level of LncRNA XLOC_109948 was detected by real-time quantitative fluorescence PCR (qRT-PCR), and the relationship between its expression and clinical characteristics was analyzed.
The expression of LncRNA XLOC_109948 in bone marrow and serum of AML patients was higher than that of AML patients with complete remission and healthy people (P<0.001). And there was no statistically significant difference between the AML-CR group and control group (P>0.05). The expression of LncRNA XLOC_109948 significantly decreased when AML patients reached to CR, and significantly increased when the disease relapsed (P<0.05). The expression of LncRNA XLOC_109948 significantly correlated with the clinicopathologic parameters of cytogenetics (P<0.05), but not significantly correlated with sex, age, WBC count, blast in bone marrow, FAB classification and other clinical characteristics (P>0.05).
The expression of LncRNA XLOC_109948 in bone marrow and serum of AML patients is high, and its expression in time and sequence is consistent between bone marrow and serum, which can reflect the occurrence, development, chemotherapy efficacy and prognosis of AML patients.
检测急性髓系白血病（AML）患者骨髓和血清中LncRNA XLOC_109948的表达水平，验证骨髓与血清中表达的一致性，并探讨LncRNA XLOC_109948表达在AML发生发展中的作用。
收集62例AML患者的骨髓和外周血样本，其中包括36例AML患者（AML组），26例完全缓解的AML患者（AML-CR组），同时收集20名健康人的外周血（对照组）。采用实时定量荧光PCR（qRT-PCR）检测LncRNA XLOC_109948的表达水平，并分析其表达与临床特征的关系。
AML患者骨髓和血清中LncRNA XLOC_109948的表达高于完全缓解的AML患者和健康人（P<0.001）。AML-CR组与对照组之间无统计学差异（P>0.05）。AML患者达到CR时，LncRNA XLOC_109948的表达显著降低；疾病复发时，表达显著升高（P<0.05）。LncRNA XLOC_109948的表达与细胞遗传学的临床病理参数显著相关（P<0.05），但与性别、年龄、白细胞计数、骨髓原始细胞、FAB分型等临床特征无显著相关性（P>0.05）。
AML患者骨髓和血清中LncRNA XLOC_109948表达较高，其在骨髓和血清中的表达在时间和序列上具有一致性，可反映AML患者的发生、发展、化疗疗效及预后。
